Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

西妥昔单抗 医学 多西紫杉醇 肿瘤科 内科学 卡铂 顺铂 头颈部 氟尿嘧啶 头颈部癌 化疗 放射治疗 癌症 外科 结直肠癌
作者
J. Guigay,Anne Aupérin,Jérôme Fayette,Esma Saâda-Bouzid,Cédrik Lafond,Miren Taberna,Lionnel Geoffrois,Laurent Martin,Olivier Capitain,Didier Cupissol,H. Castanie,Damien Vansteene,Philippe Schafhausen,Alison Johnson,Caroline Even,Christian Sire,Sophie Duplomb,Camille Evrard,Jean‐Pierre Delord,Brigitte Laguerre,Sylvie Zanetta,Cécile Chevassus-Clément,Aldéric Fraslin,Fanny Louat,Laura Sinigaglia,Ulrich Keilholz,Jean Bourhis,Ricard Mesı́a,Nabil Baba-Hamed,E. Babin,G. Béra,Sarah BETRIAN-LAGARDE,Emmanuel Blot,Emmanuelle Bompas,Christian Borel,Mohamed BOUCHEKOUA,L. Bozec Le Moal,Amandine Bruyas,G. Calais,Ioana Carpiuc,S. Chapet,Thierry Chatellier,Bruno Chauffert,Sandrine Pacquelet,Florian Clatot,Oana Zveltlana Cojocarasu,Alexandre CORNELLY,Alexandre Coutté,Pierre Dalloz,Franck Darloy,Melissa Delhommeau,D. De Raucourt,C. Debelleix,P. Debourdeau,Anne Françoise DILLIES-LEGRAIN,Pascal Dô,Catherine Dubos‐Arvis,Agnès Ducoulombier,Claude El Kouri,Sabrina Falkowski,François‐Régis Ferrand,Michel Gatineau,Radj Gervais,L. Gras,Pierre Guillet,Ali Hasbini,Stéphane HENAULT,Ruth Gabriela Herrera Gómez,F. Huguet,Marie Christine Kaminsky,Aurélie Lagrange,Sandrine Lavau‐Denès,H. Le Caer,Christine Le Foll,G. Lefebvre,B. Linot,Qian LOPEZ,Alain Lortholary,Margarida Matias,L. Mayache-Badis,Floriane Minne,Delphine Mollon,Eve Marie Neidhardt,J. Pavillet,Frédéric Peyrade,Yohann POINTREAU,Jean‐François Ramée,Camille RAUCHE,Sandrine Richard,Claudia Rizzo,Frédéric Rolland,Friderike SCHLURMANN,Laetitia Stéfani,Louis Tassy,Youssef Tazi,Jean‐Christophe Théry,Florida TORTI EL ZEIN,C. Toullec,Jean‐Marc Tourani,Philippe Toussaint,Julie Vanbockstael,Élodie Vauléon,F. Viret,Sabine WALER,Jens Atzpodien,Caecilia BEHRENS,C Busch,Andreas Dietz,Georg Feldmann,Rainer Fietkau,Thordis GRANIZKA,Jürgen GREWE,Orlando GUNTINAS-LICHINUS,Kristina HADLER-MIKESCH,D Hahn,Johanna Inhestern,K. Kellner,Konrad Klinghammer,R Kronenberger,Kerstin Lüedtke-Heckenkamp,Sebastian Ochsenreither,Burkhard Otremba,Caroline Anna Peuker,Markus Pirlich,Frank Rothmann,Mareike Tometten,Sabine Wohlfarth,Veit Zebralla,Matthias Zipfel,Juan Carlos ADANSA KLEIN,Virginia Arrazubi,J. Caballero Daroqui,Beatriz Castelo,Beatriz Cirauqui,Juan Jesús Cruz,Óscar Gallego,Lara Carmen Iglesias Docampo,Antonio López‐Pousa,Maria MARTINEZ DEL PRADO,Javier Martínez‐Trufero,Miguel Pastor Borgoñón,Elisabeth Pérez‐Ruiz,Vanesa Garcı́a,Jordi Rubió‐Casadevall,Silvia Vázquez Fernández
出处
期刊:Lancet Oncology [Elsevier]
卷期号:22 (4): 463-475 被引量:138
标识
DOI:10.1016/s1470-2045(20)30755-5
摘要

Background Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel–platinum–cetuximab) showed promising results, with a median overall survival of 14·0 months in first-line recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC). We therefore aimed to compare the efficacy and safety of the TPEx regimen with the standard of care EXTREME regimen (platinum–fluorouracil–cetuximab) in this setting. Methods This was a multicentre, open-label, randomised, phase 2 trial, done in 68 centres (cancer centres, university and general hospitals, and private clinics) in France, Spain, and Germany. Eligible patients were aged 18–70 years with histologically confirmed recurrent or metastatic HNSCC unsuitable for curative treatment; had at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1; and had an Eastern Cooperative Oncology Group (ECOG) performance status of 1 or less. Participants were randomly assigned (1:1) using the TenAlea website by investigators or delegated clinical research associates to the TPEx regimen or the EXTREME regimen, with minimisation by ECOG performance status, type of disease evolution, previous cetuximab treatment, and country. The TPEx regimen consisted of docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both intravenously on day 1, and cetuximab on days 1, 8, and 15 (intravenously 400 mg/m2 on day 1 of cycle 1 and 250 mg/m2 weekly subsequently). Four cycles were repeated every 21 days with systematic granulocyte colony-stimulating factor (G-CSF) support at each cycle. In case of disease control after four cycles, intravenous cetuximab 500 mg/m2 was continued every 2 weeks as maintenance therapy until progression or unacceptable toxicity. The EXTREME regimen consisted of fluorouracil 4000 mg/m2 on day 1–4, cisplatin 100 mg/m2 on day 1, and cetuximab on days 1, 8, and 15 (400 mg/m2 on day 1 of cycle 1 and 250 mg/m2 weekly subsequently) all delivered intravenously. Six cycles were delivered every 21 days followed by weekly 250 mg/m2 cetuximab as maintenance therapy in case of disease control. G-CSF support was not mandatory per the protocol in the EXTREME regimen. The primary endpoint was overall survival in the intention-to-treat population; safety was analysed in all patients who received at least one dose of chemotherapy or cetuximab. Enrolment is closed and this is the final analysis. This study is registered at ClinicalTrials.gov, NCT02268695. Findings Between Oct 10, 2014, and Nov 29, 2017, 541 patients were enrolled and randomly assigned to the two treatment regimens (271 to TPEx, 270 to EXTREME). Two patients in the TPEx group had major deviations in consent forms and were not included in the final analysis. Median follow-up was 34·4 months (IQR 26·6–44·8) in the TPEx group and 30·2 months (25·5–45·3) in the EXTREME group. At data cutoff, 209 patients had died in the TPEx group and 218 had died in the EXTREME group. Overall survival did not differ significantly between the groups (median 14·5 months [95% CI 12·5–15·7] in the TPEx group and 13·4 months [12·2–15·4] in the EXTREME group; hazard ratio 0·89 [95% CI 0·74–1·08]; p=0·23). 214 (81%) of 263 patients in the TPEx group versus 246 (93%) of 265 patients in the EXTREME group had grade 3 or worse adverse events during chemotherapy (p<0·0001). In the TPEx group, 118 (45%) of 263 patients had at least one serious adverse event versus 143 (54%) of 265 patients in the EXTREME group. 16 patients in the TPEx group and 21 in the EXTREME group died in association with adverse events, including seven patients in each group who had fatal infections (including febrile neutropenia). Eight deaths in the TPEx group and 11 deaths in the EXTREME group were assessed as treatment related, most frequently sepsis or septic shock (four in each treatment group). Interpretation Although the trial did not meet its primary endpoint, with no significant improvement in overall survival with TPEx versus EXTREME, the TPEx regimen had a favourable safety profile. The TPEx regimen could provide an alternative to standard of care with the EXTREME regimen in the first-line treatment of patients with recurrent or metastatic HNSCC, especially for those who might not be good candidates for up-front pembrolizumab treatment. Funding Merck Santé and Chugai Pharma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
刘明生发布了新的文献求助30
1秒前
一一应助zjw采纳,获得10
1秒前
婷妞儿完成签到,获得积分10
2秒前
重要的板凳完成签到,获得积分10
4秒前
葵秋发布了新的文献求助10
4秒前
5秒前
xly完成签到,获得积分10
5秒前
6秒前
7秒前
Beee应助刘明生采纳,获得10
7秒前
8秒前
敏酱12138完成签到,获得积分10
9秒前
内向的八宝粥完成签到,获得积分10
9秒前
10秒前
11秒前
党娟娟发布了新的文献求助10
11秒前
兔毛毛发布了新的文献求助10
12秒前
Derek0203发布了新的文献求助10
13秒前
OK不服气发布了新的文献求助10
13秒前
青檀完成签到,获得积分10
14秒前
搜集达人应助Fortune采纳,获得10
14秒前
15秒前
15秒前
大模型应助wei采纳,获得10
16秒前
成就的沛菡完成签到,获得积分10
16秒前
YA应助半夏采纳,获得10
16秒前
安生发布了新的文献求助10
17秒前
ZSZ应助Sym采纳,获得10
17秒前
青檀发布了新的文献求助10
18秒前
研友_LMN2rn完成签到,获得积分10
18秒前
19秒前
19秒前
暴躁的寻云完成签到 ,获得积分10
19秒前
CodeCraft应助兔毛毛采纳,获得10
20秒前
20秒前
顾矜应助xxiao采纳,获得30
20秒前
天天开心发布了新的文献求助10
21秒前
核动力牛马完成签到,获得积分10
21秒前
symmetry完成签到,获得积分10
21秒前
高分求助中
歯科矯正学 第7版(或第5版) 1004
SIS-ISO/IEC TS 27100:2024 Information technology — Cybersecurity — Overview and concepts (ISO/IEC TS 27100:2020, IDT)(Swedish Standard) 1000
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Semiconductor Process Reliability in Practice 720
GROUP-THEORY AND POLARIZATION ALGEBRA 500
Mesopotamian divination texts : conversing with the gods : sources from the first millennium BCE 500
Days of Transition. The Parsi Death Rituals(2011) 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3231311
求助须知:如何正确求助?哪些是违规求助? 2878497
关于积分的说明 8206311
捐赠科研通 2545904
什么是DOI,文献DOI怎么找? 1375495
科研通“疑难数据库(出版商)”最低求助积分说明 647410
邀请新用户注册赠送积分活动 622508